Below you can find all of the clinical guidelines and pathways involving medicines which are approved for use across the North East and North Cumbria ICS.

For legacy guidelines you may still need to visit the previous APC websites until a single NENC ICB version is available.

Title Documents Decision Date

Cardiovascular

Northern England Evaluation and Lipid Intensification guideline NEELI v2023.1.1 final Approved by NENC Medicines Subcommittee 17/10/2023

Central Nervous System

New

16/04/2024
NENC Agomelatine - Prescribing and Monitoring in Adults - Information for Primary Care NENC Agomelatine - Prescribing and Monitoring in Adults - Information for Primary Care - approved April 2024 Approved by NENC Medicines Subcommittee 08/04/2024

New

16/04/2024
NENC Clozapine Supporting guidance for primary care NENC Clozapine Supporting guidance for primary care - approved April 2024 Approved by NENC Medicines Subcommittee 08/04/2024

Respiratory

NENC At A Glance Supporting Greener Respiratory Care NENC At A Glance Supporting Greener Respiratory Care v2 FINAL Approved 17/10/2023
NENC Mucolytics in adults consensus guide NENC Mucolytics in Adults Consensus Guide v1.7 Approved 17/10/2023

Endocrine

Updated

16/04/2024
NENC Guidelines: Self-Monitoring of Blood Glucose and Ketones in Diabetes NENC ICB SBGM Guidance - Approved April 2024 Approved by NENC Medicines Subcommittee 08/04/2024
North East Guideline For Use Of Sodium Glucose Co transporter 2 Inhibitors (SGLT2i) NENC regional SGLT2 top tips v1.2 - NTAG approved March 2023 v2 UPDATE June 2023 Approved by NENC Medicines Subcommittee 17/10/2023
NENC Medication Management for Type 2 Diabetes in Adults Guidelines NENC Regional T2DM Guidelines FINAL v2 JUNE 2023 Approved by NENC Medicines Subcommittee 17/10/2023
Northern Region Gender Dysphoria Service - General Guidelines For The Use Of Hormone Treatment In Gender Dysphoria General Guidelines For The Use Of Hormone Treatment In Gender Dysphoria Northern Region Gender Dysphoria Service This guideline is not endorsed by NTAG or the NENC Medicines Subcommittee. Instead the link to the document on the CNTW website is included here for ease of access for those who wish to refer to it. 17/10/2023
NENC ICB - Management of the Menopause NENC-Menopause-guidance-word-FINAL APPROVED - Oct 2023 Approved by NENC Medicines Subcommittee 17/10/2023

Musculoskeletal and Joint Diseases

New

16/04/2024
NENC guideline for management of osteoporosis in primary care NENC guideline for management of osteoporosis in primary care - approved April 2024 Approved by NENC Medicines Subcommittee 08/04/2024

Obstetrics, gynaecology, and urinary tract

North of Tyne, Gateshead and North Cumbria Urinary Catheter Care Product Formulary 2023 NoTGNC Catheter Formulary 2023 V7 Approved 05/12/2023
Management of Symptomatic Recurrent Uncomplicated Urinary Tract Infections in Adult Women recurrent-uti-ics-final-guidance-february-2023 Approved 21/02/2023

Renal

SGLT2-inhibitors and Chronic Kidney Disease - Patient Information Leaflet SGLT2 CKD PIL NTAG v1 Approved by NTAG 07/06/2022
Finerenone for treating chronic kidney disease in people with type 2 diabetes NENC Finerenone_CKD_type 2 diabetes_v6 - approved feb 2024 Approved by NENC Medicines Subcommittee 12/02/2024

Miscellaneous

New

16/04/2024
Abnormal Liver blood test Guidelines NENC Hepatology Network V3 NENC Abnormal Liver blood test Guidelines NENC Hepatology Network V3.0 Approved for hosting on NTAG website. 08/04/2024
NENC Penicillin Allergy Assessment Oral Challenge and De-labelling Secondary Care - June 2023 NENC Penicillin Allergy Assessment Oral Challenge and De-labelling Secondary Care - June 2023 Approved by NENC Medicines Subcommittee 20/06/2023
NENC Penicillin Allergy Assessment primary care for adult patients - approved Feb 2024 NENC Penicillin Allergy Assessment primary care - approved Feb 2024 Approved by NENC Medicines Subcommittee 12/02/2024
NENC Position statement on the prescribing of branded generic medication NENC Position statement on Branded Generics v2 - approved Feb 2024 Approved by NENC Medicines Subcommittee 12/02/2024